Chronic Kidney Disease: Effects on the Cardiovascular System
暂无分享,去创建一个
[1] M. Cheitlin,et al. Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2008 .
[2] J. Griffith,et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.
[3] K. Homma,et al. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.
[4] W. März,et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). , 2007, Clinical chemistry.
[5] M. Shlipak,et al. Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2006, Circulation.
[6] F. Locatelli,et al. Anemia and cardiovascular risk: the lesson of the CREATE Trial. , 2006, Journal of the American Society of Nephrology : JASN.
[7] R. Jofré,et al. Inflammatory syndrome in patients on hemodialysis. , 2006, Journal of the American Society of Nephrology : JASN.
[8] J. Loscalzo,et al. Vascular Calcification: Pathobiological Mechanisms and Clinical Implications , 2006, Circulation research.
[9] C. Wanner,et al. Cross-talk between the kidney and the cardiovascular system. , 2006, Journal of the American Society of Nephrology : JASN.
[10] C. Stehouwer,et al. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. , 2006, Journal of the American Society of Nephrology : JASN.
[11] T. Imaizumi,et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.
[12] S. Solomon,et al. Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial , 2006, Circulation.
[13] M. Tonelli,et al. Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.
[14] A. Garg,et al. Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.
[15] J. Floege,et al. Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon , 2006, Hypertension.
[16] R. Trevisan,et al. Lipids and renal disease. , 2006, Journal of the American Society of Nephrology : JASN.
[17] S. Cummings,et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. , 2005, Journal of the American Society of Nephrology : JASN.
[18] I. Jaussent,et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.
[19] C. Zoccali,et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] L. Bouter,et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. , 2006, Journal of the American Society of Nephrology : JASN.
[21] P. Chaves,et al. Kidney function as a predictor of noncardiovascular mortality. , 2005, Journal of the American Society of Nephrology : JASN.
[22] W. Qunibi. Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.
[23] M. Pfeffer,et al. Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease , 2005, Circulation.
[24] F. Kronenberg,et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.
[25] C. Zoccali,et al. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] Carmine Zoccali,et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. , 2005, Journal of the American Society of Nephrology : JASN.
[27] W. C. O'Neill,et al. Reduced plasma pyrophosphate levels in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.
[28] K. Hruska,et al. Bone Morphogenetic Proteins in Vascular Calcification , 2005, Circulation research.
[29] N. Chen,et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). , 2005, Kidney international.
[30] P. Stenvinkel,et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. , 2005, Kidney international.
[31] D. Siscovick,et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.
[32] Xiaoqiang Yao,et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. , 2005, The Journal of clinical investigation.
[33] R. Nelson,et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.
[34] L. Fried,et al. Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults , 2005, Annals of Internal Medicine.
[35] R. Terkeltaub,et al. Chondrogenesis Mediated by PPi Depletion Promotes Spontaneous Aortic Calcification in NPP1−/− Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[36] J. Passauer,et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. , 2005, Journal of the American Society of Nephrology : JASN.
[37] M. Safar,et al. Stiffness of Capacitive and Conduit Arteries: Prognostic Significance for End-Stage Renal Disease Patients , 2005, Hypertension.
[38] E. Schiffrin,et al. p47phox Associates With the Cytoskeleton Through Cortactin in Human Vascular Smooth Muscle Cells: Role in NAD(P)H Oxidase Regulation by Angiotensin II , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[39] M. Nieminen,et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.
[40] V. Andreucci,et al. Coronary artery calcification in patients with CRF not undergoing dialysis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] Di Chen,et al. Bone Morphogenetic Proteins , 2004, Growth factors.
[42] H. Gerstein,et al. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. , 2004, Kidney international. Supplement.
[43] M. Pfeffer,et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. , 2004, Kidney international. Supplement.
[44] L. Schurgers,et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. , 2004, Journal of the American Society of Nephrology : JASN.
[45] L. Bouter,et al. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction--the Hoorn Study. , 2004, Kidney international. Supplement.
[46] Robert M Califf,et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.
[47] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[48] E. Schiffrin,et al. Reactive oxygen species in vascular biology: implications in hypertension , 2004, Histochemistry and Cell Biology.
[49] B. Brenner,et al. Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.
[50] E. Schiffrin,et al. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. , 2004, American journal of physiology. Heart and circulatory physiology.
[51] K. Borch-Johnsen,et al. Preventive cardiology: abstractVery low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes☆ , 2004 .
[52] P. Vallance,et al. Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[53] P. Blankestijn,et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. , 2004, Kidney international.
[54] J. Cooke. Asymmetrical Dimethylarginine: The Über Marker? , 2004, Circulation.
[55] R. Terkeltaub,et al. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. , 2004, The American journal of pathology.
[56] J. Eiserich,et al. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. , 2004, Journal of the American Society of Nephrology : JASN.
[57] H. Parving,et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. , 2004, Diabetes care.
[58] S. Saito,et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography , 2004, Thrombosis and Haemostasis.
[59] C. Zoccali,et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.
[60] D. Tsikas,et al. Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.
[61] Ernesto L. Schiffrin,et al. Endothelial dysfunction. , 2004, Journal of the American Society of Nephrology : JASN.
[62] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[63] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.
[64] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.
[65] K. Nitta,et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[66] P. Stenvinkel,et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[67] P. Stenvinkel,et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. , 2003, Kidney international. Supplement.
[68] C. Wanner,et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.
[69] D. Grobbee,et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.
[70] D. Kereiakes,et al. Endothelial dysfunction. , 2003, Circulation.
[71] N. Hollenberg,et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. , 2003, Kidney international.
[72] N. Vaziri,et al. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. , 2003, Kidney international.
[73] Peter Stenvinkel,et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.
[74] Patricia Ducy,et al. Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.
[75] M. Mcclellan,et al. Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.
[76] Hans L Hillege,et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.
[77] B. Dahlof,et al. Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol☆ , 2002 .
[78] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[79] K. Boström,et al. Matrix GLA Protein, a Regulatory Protein for Bone Morphogenetic Protein-2* , 2002, The Journal of Biological Chemistry.
[80] Will F. Figueira,et al. Discovery of a High Molecular Weight Complex of Calcium, Phosphate, Fetuin, and Matrix γ-Carboxyglutamic Acid Protein in the Serum of Etidronate-treated Rats* , 2002, The Journal of Biological Chemistry.
[81] M. Rathaus,et al. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. , 2002, Kidney international.
[82] C. Zoccali,et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[83] N. Vaziri,et al. Enhanced Nitric Oxide Inactivation and Protein Nitration by Reactive Oxygen Species in Renal Insufficiency , 2002, Hypertension.
[84] D. Fliser,et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[85] C. Zoccali,et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.
[86] E. Ritz,et al. Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade. , 2001, Journal of the American Society of Nephrology : JASN.
[87] J. Blacher,et al. Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal Disease , 2001, Hypertension.
[88] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[89] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[90] D. Fliser,et al. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[91] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[92] F. Parhami,et al. Leptin Enhances the Calcification of Vascular Cells: Artery Wall as a Target of Leptin , 2001, Circulation research.
[93] S. Yusuf,et al. Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.
[94] C. Wanner,et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[95] A. Zanchetti,et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.
[96] A. Charlesworth,et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.
[97] P. Stenvinkel,et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[98] D. Levy,et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.
[99] Coleman Tg,et al. Quantitative analysis of the pathophysiology of hypertension. 1969. , 1999 .
[100] R. Foley,et al. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease and cardiac failure. Semin Dial 2003 , 2022 .
[101] G. Eknoyan,et al. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[102] M. Hijmering,et al. Nitric oxide production is reduced in patients with chronic renal failure. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[103] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[104] R. Foley,et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[105] A. Fitzgerald,et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. , 1998, Diabetes.
[106] A. Collins,et al. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.
[107] E. Ritz,et al. Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.
[108] N. Vaziri,et al. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. , 1998, Kidney international.
[109] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[110] J. Skepper,et al. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[111] B. Kasiske,et al. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. , 1997, Kidney international. Supplement.
[112] A. Skene,et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure , 1997, The Lancet.
[113] F. Fabbian,et al. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[114] R. Behringer,et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein , 1997, Nature.
[115] M. Budisavljevic,et al. Calciphylaxis in chronic renal failure. , 1996, Journal of the American Society of Nephrology : JASN.
[116] Howard C. Tenenbaum,et al. Fetuin/α2-HS Glycoprotein Is a Transforming Growth Factor-β Type II Receptor Mimic and Cytokine Antagonist* , 1996, The Journal of Biological Chemistry.
[117] David C. Murray,et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. , 1996, Kidney international.
[118] J. Singer,et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[119] A. Schwarz,et al. Severe calciphylaxis in a renal patient on long-term oral anticoagulant therapy. , 1996, American journal of nephrology.
[120] G. Burg,et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. , 1995, Journal of the American Academy of Dermatology.
[121] R. Zatz,et al. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. , 1995, Journal of the American Society of Nephrology : JASN.
[122] David C. Murray,et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.
[123] A. Daugherty,et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.
[124] P. Weissberg,et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[125] R. Converse,et al. Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.
[126] S. Moncada,et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.
[127] M. Blaufox,et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. , 1989, Hypertension.
[128] W. Kannel,et al. The prognostic significance of proteinuria: the Framingham study. , 1984, American heart journal.
[129] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[130] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[131] D. J. Patel,et al. The Elastic Symmetry of Arterial Segments in Dogs , 1969, Circulation research.
[132] T. G. Coleman,et al. Quantitative analysis of the pathophysiology of hypertension. , 1969, Circulation research.